Aktiv, aber nicht rekrutierendPHASE1INTERVENTIONELL

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

This research study is about a new medicine called ARGX-119 for adults who have a rare muscle condition called DOK7-Congenital Myasthenic Syndrome (CMS). The main goal is to check if ARGX-119 is safe and how well people can tolerate it. Researchers will also learn how the body handles the medicine and if it might improve health and daily activities for those with DOK7-CMS. Participants will either receive the new medicine or a dummy medicine (placebo) first, without knowing which one they are getting. After a period, everyone will have the chance to receive the new medicine. The study will last for about 38 months.

Auf einen Blick

Status

Aktiv, aber nicht rekrutierend

Phase

PHASE1

Sponsor

argenx

Einschreibeziel

Starten

24 Sep 2024

Geschätzte Fertigstellung

24 Jan 2028

Congenital Myasthenic Syndrome CMS

Worum geht es in dieser Studie?

You might be reading this because you, or someone you know, has a condition called DOK7-Congenital Myasthenic Syndrome (CMS). This is a rare, inherited condition that causes muscle weakness. Scientists are always working to find new and better ways to treat conditions like yours, and this study is part of that effort.

This study is testing a new medicine called ARGX-119. It's an early-stage study, meaning it's one of the first times this medicine is being given to people. The main things researchers want to find out are whether the medicine is safe and if people can take it without too many problems. They'll also be looking at how your body processes the medicine and if your immune system reacts to it. Importantly, the study will also try to see if ARGX-119 helps improve how you feel and what you can do each day.

Understanding how new medicines work is a long process, and studies like this are a vital step. By taking part, you could help researchers learn more about DOK7-CMS and contribute to future treatments for this condition.

Wichtige Erkenntnisse

This is a study of a new medicine, ARGX-119, for DOK7-Congenital Myasthenic Syndrome (CMS).
Its main aim is to check if the medicine is safe and well-tolerated by adults.
Participants will receive either the study medicine or a dummy medicine (placebo) first.
The total study time will be about 38 months (just over 3 years).
Your participation could help advance understanding and treatment for DOK7-CMS.
You can stop participating at any time if you change your mind.

Wer könnte berechtigt sein?

To join this study, you need to be an adult, at least 18 years old, and have a confirmed diagnosis of DOK7-Congenital Myasthenic Syndrome. This diagnosis must be based on a genetic test showing changes in the DOK7 gene.

If you take certain oral medicines for your breathing, like albuterol or salbutamol (often called 'beta agonists'), you must have been taking them for at least three months and be willing to continue on the same dose throughout the study period.

There are also some reasons why you might not be able to join. For example, if your CMS is caused by a different genetic problem. You also can't take part if you have other serious medical conditions that might make it hard to tell if the study medicine is working, or if it could put you at risk. This includes having certain types of cancer that haven't been cured for more than five years. Pregnant or breastfeeding women, or those planning to become pregnant, cannot participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

Sind Sie 18 Jahre alt oder älter?
Do you have a genetically confirmed diagnosis of DOK7-Congenital Myasthenic Syndrome?
If you take certain oral breathing medicines (like albuterol), have you been on the same dose for at least 3 months and can you stay on it?
Are you not pregnant, breastfeeding, or planning to become pregnant during the study?
Do you have any other serious medical conditions that a doctor might consider risky for a study?
Have you been clear of most cancers for at least 5 years (some minor cancers are allowed)?

Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, you'll first go through a screening process to make sure the study is right for you. If you're eligible, you'll then be randomly assigned to receive either the new medicine, ARGX-119, or a dummy medicine called a placebo. Neither you nor your study doctor will know which you are receiving during this first part of the study; this is called 'double-blinded'. These medicines are given through a drip into your arm (intravenous infusions).

After this first treatment period, there will be a follow-up period. Once that's complete, you might be able to join an 'open-label' period, where everyone receives ARGX-119, and both you and the study team will know you're getting the active medicine. The full study, from start to finish, will take approximately 38 months, which is just over three years.

Potenzielle Risiken und Vorteile

Taking part in any medical study has potential benefits and risks. You might feel better or experience an improvement in your symptoms with the study medicine, but there's no guarantee it will help you. There's also a chance that the medicine could cause side effects. These could be mild or, in rare cases, more serious. All risks and potential benefits will be explained in detail before you decide to join. Remember, taking part in a study is always voluntary, and you can change your mind and withdraw at any time, for any reason, without it affecting your usual medical care.

Standorte (9)

UC Davis Medical Center
Verifizierte Postleitzahl
Sacramento, Vereinigte Staaten
Ann and Robert H Lurie Childrens Hospital of Chicago
Verifizierte Postleitzahl
Chicago, Vereinigte Staaten
Ottawa Hospital Research Institute - Civic Campus
Verifizierte Postleitzahl
Ottawa, Kanada
CHU - Hospital de la Timone
Verifizierte Postleitzahl
Marseille, Frankreich
Group Hospitalier Pitie-Salpetriere
Verifizierte Postleitzahl
Paris, Frankreich
Fondazione IRCCS Istituto Neurologico Carlo Besta
Verifizierte Postleitzahl
Mailand, Italien
Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
Verifizierte Postleitzahl
Valencia, Spain
Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital
Verifizierte Postleitzahl
Belfast, Vereinigtes Königreich
John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust
Verifizierte Postleitzahl
Oxford, Vereinigtes Königreich

Häufige Fragen

What is DOK7-Congenital Myasthenic Syndrome (CMS)?

It's a rare, inherited condition that causes muscle weakness throughout the body, starting at or around birth.

What does 'Phase 1b Study' mean?

It means this is an early-stage study primarily focused on checking the safety of the new medicine and finding the right dose in people who have the condition.

Why is a placebo used in the study?

Using a placebo helps researchers fairly compare the new medicine's effects against not receiving the active medicine, giving a clearer picture of its true benefits and side effects.

Muss ich bezahlen, um an der Studie teilzunehmen?

No, you will not have to pay for the study medicine or study-related visits and tests.

Was passiert, wenn ich während der Studie schwanger werde?

If you are or become pregnant, you cannot participate in this study. It's important to use effective birth control methods if you are able to become pregnant.

Wie Sie mehr erfahren können

Offizielles Gerichtsprotokoll

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.